[1] 俞菁,俞琼琰,李海川.孕期无创产前检测胎儿分数与子痫前期孕妇妊娠结局的相关性分析[J].中国妇幼保健,2023,38(22):4462-4465.
[2] 薛莹,丁洁,贺权泽,等.孕妇年龄、孕周及体重指数对孕妇外周血中胎儿游离DNA比例的影响[J].中国产前诊断杂志(电子版),2017,9(3):5-10.
[3] CERNAT A, DE FREITAS C, MAJID U, et al. Facilitating informed choice about non-invasive prenatal testing (NIPT): a systematic review and qualitative meta-synthesis of women’s experiences. BMC Pregnancy Childbirth. 2019;19(1):27.
[4] DENG C, LIU J, LIU S, et al. Maternal and fetal factors influencing fetal fraction: A retrospective analysis of 153,306 pregnant women undergoing noninvasive prenatal screening. Front Pediatr. 2023;11:1066178.
[5] SUN D, LI F, ZHANG Y, et al. Associations of the pre-pregnancy BMI and gestational BMI gain with pregnancy outcomes in Chinese women with gestational diabetes mellitus. Int J Clin Exp Med. 2014;7(12):5784-5789.
[6] KIM SH, HONG YM, PARK JE, et al. The Association between Low Fetal Fraction of Non-Invasive Prenatal Testing and Adverse Pregnancy Outcomes for Placental Compromise. Diagnostics (Basel). 2024;14(10):1020.
[7] ASHOOR G, SYNGELAKI A, POON LC, et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013;41(1):26-32.
[8] TAYLOR JB, CHOCK VY, HUDGINS L. NIPT in a clinical setting: an analysis of uptake in the first months of clinical availability. J Genet Couns. 2014;23(1):72-78.
[9] ZHANG H, GAO Y, JIANG F, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol. 2015;45(5):530-538.
[10] NORTON ME, WAPNER RJ. Cell-free DNA Analysis for Noninvasive Examination of Trisomy. N Engl J Med. 2015;373(26):2582.
[11] PALOMAKI GE, KLOZA EM, LAMBERT-MESSERLIAN GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011;13(11):913-920.
[12] BIANCHI DW, PLATT LD, GOLDBERG JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012;119(5):890-901.
[13] GIL MM, QUEZADA MS, REVELLO R, et al. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015;45(3):249-266.
[14] CANICK JA, KLOZA EM, LAMBERT-MESSERLIAN GM, et al. DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. Prenat Diagn. 2012;32(8):730-734.
[15] PORRECO RP, GARITE TJ, MAUREL K, et al. Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. Am J Obstet Gynecol. 2014;211(4):365.e1-12.
[16] DAR P, CURNOW KJ, GROSS SJ, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol. 2014;211(5):527.e1-527.e17.
[17] PERGAMENT E, CUCKLE H, ZIMMERMANN B, et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol. 2014;124(2 Pt 1):210-218.
[18] NICOLAIDES KH, SYNGELAKI A, DEL MAR GIL M, et al. Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood. Fetal Diagn Ther. 2014;35(3):212-217.
[19] SEHNERT AJ, RHEES B, COMSTOCK D, et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem. 2011;57(7):1042-1049.
[20] SPARKS AB, STRUBLE CA, WANG ET, et al. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;206(4):319.e1-9.
[21] CHIU RW, AKOLEKAR R, ZHENG YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ. 2011;342:c7401.
[22] EHRICH M, DECIU C, ZWIEFELHOFER T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol. 2011;204(3):205.e1-11.
[23] LIANG D, LV W, WANG H, et al. Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing. Prenat Diagn. 2013;33(5):409-415.
[24] LAU TK, CHEUNG SW, LO PS, et al. Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center. Ultrasound Obstet Gynecol. 2014; 43(3):254-264.
[25] HU T, WANG J, ZHU Q, et al. Clinical experience of noninvasive prenatal testing for rare chromosome abnormalities in singleton pregnancies. Front Genet. 2022;13:955694.
[26] ZHANG J, LI J, SAUCIER JB, et al. Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA. Nat Med. 2019; 25(3):439-447.
[27] RABINOWITZ T, SHOMRON N. Genome-wide noninvasive fetal screening: just a fantasy. Expert Rev Mol Diagn. 2012;12(8):799-801.
[28] FAN HC, QUAKE SR. Sensitivity of noninvasive prenatal detection of fetal aneuploidy from maternal plasma using shotgun sequencing is limited only by counting statistics. PLoS One. 2010;5(5):e10439.
[29] LO YM, CORBETTA N, CHAMBERLAIN PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485-487.
[30] CHIU RW, CHAN KC, GAO Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A. 2008;105(51):20458-20463.
[31] FAN HC, BLUMENFELD YJ, CHITKARA U, et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A. 2008; 105(42):16266-16271.
[32] CHEN EZ, CHIU RW, SUN H, et al. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS One. 2011;6(7):e21791.
[33] LAU TK, CHAN MK, LO PS, et al. Clinical utility of noninvasive fetal trisomy 21 testing using maternal plasma DNA. Prenat Diagn. 2012;32(10):996-998.
[34] DAN S, WANG W, REN J, et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn. 2012;32(13):1225-1232.
[35] WANG JC, SAHOO T, SCHONBERG S, et al. Discordant noninvasive prenatal testing and cytogenetic results: a study of 109 consecutive cases. Genet Med. 2015;17(3):234-236.
[36] GRATI FR, MALVESTITI F, FERREIRA JC, et al. Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. Genet Med. 2014;16(8):620-624.
[37] PAN M, LI FT, LI Y, et al. Discordant results between fetal karyotyping and non-invasive prenatal testing by maternal plasma sequencing in a case of uniparental disomy 21 due to trisomic rescue. Prenat Diagn. 2013;33(6):598-601.
[38] CHOI H, LAU TK, JIANG FM, et al. Fetal aneuploidy screening by maternal plasma DNA sequencing: ‘false positive’ due to confined placental mosaicism. Prenat Diagn. 2013;33(2):198-200.
[39] MAO J, WANG T, WANG BJ, et al. Confined placental origin of the circulating cell free fetal DNA revealed by a discordant non-invasive prenatal test result in a trisomy 18 pregnancy. Clin Chim Acta. 2014;433:190-193.
[40] HALL AL, DRENDEL HM, VERBRUGGE JL, et al. Positive cell-free fetal DNA testing for trisomy 13 reveals confined placental mosaicism. Genet Med. 2013;15(9):729-732.
[41] WANG Y, ZHU J, CHEN Y, et al. Two cases of placental T21 mosaicism: challenging the detection limits of non-invasive prenatal testing. Prenat Diagn. 2013;33(12):1207-1210.
[42] CANICK JA, PALOMAKI GE, KLOZA EM, et al. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn. 2013;33(7):667-674.
[43] WANG E, BATEY A, STRUBLE C, et al. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013;33(7):662-666.
[44] ASHOOR G, POON L, SYNGELAKI A, et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: effect of maternal and fetal factors. Fetal Diagn Ther. 2012;31(4):237-243.
[45] HOU Y, YANG J, QI Y, et al. Factors affecting cell-free DNA fetal fraction: statistical analysis of 13,661 maternal plasmas for non-invasive prenatal screening. Hum Genomics. 2019;13(1):62.
[46] ZHOU Y, ZHU Z, GAO Y, et al. Effects of Maternal and Fetal Characteristics on Cell-Free Fetal DNA Fraction in Maternal Plasma. Reprod Sci. 2015;22(11):1429-1435.
[47] ZHANG Y, ZHAO L, LI H, et al. The relationship between maternal characteristics and fetal fraction in non-invasive prenatal testing: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2021;34(24):4091-4100.
[48] WRIGHT D, WRIGHT A, NICOLAIDES KH. A unified approach to risk assessment for fetal aneuploidies. Ultrasound Obstet Gynecol. 2015;45(1): 48-54.
[49] KINNINGS SL, GEIS JA, ALMASRI E, et al. Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing. Prenat Diagn. 2015;35(8):816-822.
[50] BENN P, CUCKLE H, PERGAMENT E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol. 2013;42(1):15-33.
[51] MINEAR MA, LEWIS C, PRADHAN S, et al. Global perspectives on clinical adoption of NIPT. Prenat Diagn. 2015;35(10):959-967.
|